```
١.
                                              flurbiprofen
                                                         arachidonic acid metabolism
                                            cyclooxygenase pathway
             가
                                                                    7 - 13)
                                                                         (dexametha -
                             1,2)
                                                   cortisol
                                                      Dex
                                            sone,
                   3),
                                   4)
가
                    5,6)
                                                                  14,15)
                1,2)
                                                       16).
                                           가
                                           17 - 21)
    propionic acid
                             ibuprofen
```

1996

22 - 24)						
		25 - 29).		II.		
Sisson <sup>24)</sup> 가			1.	( )		
Chyun <sup>30</sup> 가	가 , 1	Гaylor <sup>31)</sup>	) , 가	(Gibco , , , fetal , FBS , - c acid(Sigma,	- M bovine se ) glycerop	ed eagle IEM erum(Gibco phosphate, amethasone
	96		2.			
DNA <sup>32,33)</sup> , 24 , 가	Dex	DNA 34-35). ang - acting 6),	cells/we - glyce , 1000 mycin 37	0 <sup>5</sup> cells/well, 24 Il 10% fetal berophosphate, J/ml penicilline - MEN , 5% CO <sub>2</sub>	l well plat povine ser 50μg/ml e, 100μg/m	um, 10mM
27),			. 10%	fetal bovine se - 1	, Dex	48
, 가	Dex 36). 37), 38)		3	ree media , serum free m 10 <sup>-7</sup> M Dex	edia	- 2 24 Dex
Dex	30)		3.			5 40 45
가 ,			20, 25		well	5, 10, 15, 0.05%
	Dex ,		Trypsin/0.02% EDTA 가 well			
	가		hemocy	tometer		

SAS program ANOVA test

4. ALP

24 well plate 10<sup>-7</sup>M Dex 가 3 5 , 10 , 15 , 20 , 25 ALP p-nitrophenyl phosphate(Sigma, USA)

(phosphate buffered saline, PBS) 2 0.02%




Figure 1. Time - response effect of Dex on Cell growth activity of MC3T3 - E1 cells cultured for 5, 10, 15, 20, 25 days.

MC3T3 - E1 cells were seeded at 1 × 10<sup>4</sup> cells/ml in alpha - minimum essential medium containing 10 % fetal bovine serum, 10 mM - glycerophosphate and 50 $\mu$ g/ml of ascorbic acid. Before 48 hours of indicated time, medium were changed with serum free medium containing 10 mM - glycerophosphate, 10 M dexamethasone and 50 $\mu$ g/ml of ascorbic acid.. Cell growth activity were measured as described in materials and methods. Each value represents the mean and S.D.( × 10<sup>4</sup> cells)/200 $\mu$ l/well of five determinants.

\*: significantly different from control - 1 value in dose resoponse effect (P < 0.05)

Nonidet P - 40(Sigma) 1ml ultra sonicator 15 sonication (Fischer, Rockville, MD) 12,000g 15

. BCA protein assay reagent(Pierce, USA) , bovine serum albumin standard ,




Figure 2. Time - response effect of Dex on ALP activity of MC3T3 - E1 cells cultured for 5, 10, 15, 20, 25 days.

MC3T3 - E1 cells were seeded at 1 × 10<sup>4</sup> cells/ml in alpha - minimum essential medium containing 10% fetal bovine serum, 10 mM - glycerophosphate and 50 $\mu$ g/ml of ascorbic acid. Before 48 hours of indicated time, medium were changed with serum free medium containing 10 mM - glycerophosphate, 10<sup>-7</sup>M dexamethasone and 50 $\mu$ g/ml of ascorbic acid. Cell growth activity were measured as described in materials and methods. Each value represents the mean and S.D.( × 10<sup>4</sup> cells)/200 $\mu$ l/well of five determinants.

\* : significantly different from control - 1 value in dose resoponse effect (P < 0.05)

ALP nmole/min/mg of protein				4.25	± 0.31	가	가, 15		
				3.35	± 1.17	', 20	2.0	1 ± 0.16	, 25
SAS prog	gram ANOV	ANOVA test		$0.86 \pm 0.54$					
					- 2	5	3.4	$14 \pm 0.60$	)
5. Histochemical analysis				, 10		$9.00 \pm$	2.00	가	
				15	5	$.33 \pm 1.03$	3,20		2.33
			30	± 0.87	25	1.3	84 ± 1.12	2	
100mn	n dish	,			,	- 1		ALP	
		ice - colo	PBS		(P<0	0.05).			
2		1	0.1%	Dex		5	1.4	4 ± 0.06	6
Alizarin Red S			10 1.16±0.12						
	1% light gree	n SF solut	ion	,					
	0 0	0.1% ace		,		15	2.52 ±	0.42 ,	20
absolute	ethanol		15, 20,	4	56 ± 0.			,	
25	othano.	0, 10,	.0, 20,	25	1.58 :		•		,
20		•		20	1.00 -	2 0.00			
III.				(	P<0.0	5).			
				`		,			
1.				3.					
							20		
Dex		,	15	,	25				
		20	가	,		D	ex	10	
,					,				가
. (P<0	0.05)( Figure	1 )			,			(F	igure
,	3 , ( 9	,		3 - 7	).			`	3
2. ALP					,-				
					ı	V.			
	MC3T	3 - E1	ALP		•	••			
	- 1, -								
가 그	', 가	2 1							,
Dex		0	,	1),	,				
Dex		· - 가 25		,					
	, ,	r /r25						•	
	, 10								
	•	(D -0.0E)						가	
MCOTO		(P<0.05)			,			- 1	
MC3T3 -		ALP					2	24 - 26)	
	ng of protein	4 . 0.57	,				_	<b>'•</b>	
- 1	5 2.0	$4 \pm 0.57$	10						

```
Hiroko Sudo 39)
                      27 - 34)
                                                                     16
           27 - 34)
                                                              30
                                                                 가
                                                                         가
           dex
               가
                                                 40)
                               dex
                                                          Dex가
                           가
                                                   가
                          MC3T3-E1
              , ALP
                                                                           15
                                                       Dex
                                                                , 20
    Dex
                          26 - 31)
                                                   Dex가
                                          ALP
    10<sup>-7</sup>M
                                                                     Robinson
                                          44)
 MC3T3-E1
                                                                    , Siffert45)
                             39 - 41)
              MC3T3 - E1
                                          Stein 46)
                                                                       ALP
                                                                  ALP
                         40,41)
osteocalcin
                                                                   MC3T3 - E1
         42,43)
                                41)
                                              ALP
       MC3T3 - E1
                                               - 1,
                                                         - 2
                                                                 10
                                        가
                                              가
                                                                        , Dex
                                                      가
            MC3T3 - E1
                                 Dex
                                                10
                                                가
                             , 20
                                                47)
                                                             10
                                                                       15
                                                                         48)
                          10
                                               ALP
               Dex
                                        Nojima
                                                49)
                                                                        ALP
   가
                                             가
                                                                   가
                                                            , MC3T3 - E1
                                                                 가 ,10
MC3T3 - E1 21
                                        ALP
```

41) , Dex가 , ALP 가 ALP , Dex가 Dex 가 ALP Dex가 VI. 가 1. Lindhe, J.: Textbook of clinical peri -٧. odontology, 2nd ed., Munksguard, Copenhagen, pp. 50, 1989. 2. pp. 473 - 476, 1992. 3. Cobi, J. L., Ayala, G., Miron, W.: Dex Clinical and biologic observation of Dex가 demineralized freeze - dried bone allo grafts in augmentation procedures around dental implants, Int. J. Oral Dex Maxillofac. Implants, 9: 586 - 592, Dex 5, 10, 15, 1994. 4. Michael, E. F., Jay, M., David, K., 20, 25 Marjorie, J., Ross, H., Laura, D. B., Jack L.: The use of guided bone regeneration to fill large mandibular 1. Dex defects in monkeys; A pilot study, Int. , 15 J., Oral Maxillofac. Implants, 9: 644 -10 Dex 652, 1994. 20 5. Lynch, S. E., Buser, D., Hernandes, R. 가 A., Weber, H. P., Stich, H., Fox, C. H., (p < 0.05).Williams, R. C.: Effects of the platelet 2. MC3T3 - E1 derived growth factor/insulin like ALP growth factor - I combination on bone - 1, - 2 가 가 10 regeneration around titanium dental implants. Results of a pilot study in Dex 10 가 beagle dogs, J. Periodontol., 62: 710 -716, 1991. 6. Cochran, D. L., Rouse, C. A., Lynch, S. (p < 0.05).

- E., Graves, D. T.: Effects of platelet derived growth factor isoforms on calcium release from neonatal mouse calvariae, Bone, 14:53 58, 1993.
- Offenbacher, S., Braswell, L.D., Loos, A.S., et al.: Effects of flurbiprofen on the prgression of periodontitis in Macaca mulatta. J. Periodont. Res., 24:473, 1987.
- Offenbacher, S., Odle, B.M., Braswell, L.D., et al.: Changes in cyclooxygenase metabolites in experimental periodon titis in Macaca mulatta. J. Periodont. Res., 24:63, 1989.
- Williams, R.C., Jeffcoat, M.K., Howell, T.H., et al: Ibuprofen: An inhibitor of alveolar bone resorption in beagles. J. Periodont. Res., 23:225, 1988.
- Williams, R.C., Jeffcoat, M.K., Kaplan, M.L., Goldhabor, P., Johnson, G. H.,and Wechter, W.J.: Flurbiprofen: A potent inhibitor of alveolar bone resorption in beagles. Science, 227:640, 1985.
- Williams, R.C., Jeffcoat, M.K., Howell, T.H., et al.: Topical flurbiprofen treatment of periodontitis in beagles. J. Periodont. Res., 23:166, 1988.
- Jeffcoat, M.K., Williams, R.C., Reddy, M.S. et al.: Flurbiprofen treatment of human periodontitis: effect in alveolar bone height and metabolism. J. Periodont Res., 23:381, 1988.
- Jeffcoat, M.K., Williams, R.C., Wechter, R.J., et al.: Flurbiprofin treatment of periodontal disease in beagles. J. Periodont. Res., 21:624, 1986.
- 14. :

- , pp. 125 127, 163, 1985.
- 15. Carranza, F.A.: Glickman's clinical periodontolgy 6th ed. Saunders Co.: pp. 72 474, 1984.
- Cupta, O.P., Blechman, H. and Stahl, S.S.: The effect of stress in the periodontal tissue of young adult male rats and hamsters. J. Periodontol 31: 413-417, 1960.
- 17. Sissons, H.A. and Hadfield, G.J.: The influence of cortisone in the rabbit. Br. J. Surg 39: 172 178, 1951.
- 18. Bellows, C.G., Heersche, J.N. & Aubin, J.E.: Determination of the capacity for proliferation and differentiation of osteoprogenitor cells in the presence and abscence of dexamethasone. Dev. Biol.. 140: 132-138, 1990.
- Kasugai, S., Todescan, R., Nagata, T., Yao, K L, Butler, W.T. & Sodek, J. : Expression of bone matrix proteins associate with mineralized tissue formation by adult marrow cells in vitro; inductive effects of dexamethasone on osteoblast phenotybe. J. cell physiol. 147: 11-120, 1991.
- Baylink, D.J.: Glucocorticoid induced osteoporosis. N. Engl. J. Med: 309 - 308, 1983.
- 21. Burckhardt, P.: Corticosteroids and bone. A review, Hormone Res. 20; 59-64, 1984.
- Meunier, P.J., Dempster, D.W., Edouard, C., Chapuy, M.C., Arlot M., Charon, S.: Bone histomorphometry in syndrome. Adv. Exp. Med. Biol. 171: 191, 1984.
- 23. Jowsey, J., Riggs, B.L.: Bone for -

- mation in hypercorticism. Acta. Endocrinol. 63: 21, 1970.
- Jee Wss, Park HY, Roberto WE, Kanner GH: Coticosteroid and bone.
   Am. J. Anat. 129: 477, 1970.
- Blunt, J.W., Plotz, C.M., Latters, R., Howes, E.L., Meyer, K., and Ragan, C.
   Effect of cortisone on experimental fractures in the rabbit. Proc. Soc. Exp. Biol. Med. 73: 678 - 681, 1950.
- Kostenszky, K.S. and Olah, E.H.:
   Effect of prednisolone on Callus formation Acta. Biol. Acad. Sci. Hung 25: 49-60, 1974.
- 27. Murakami, H. and Kowalewski, K.: Effect of cortisone and on anabolic androgen on the fractured humerus in guinea pigs. Clinical and histological study over a six - week period of fracture healing can. J. Surg. 9: 425 - 434, 1966.
- 28. Ragan, C., Grokoest, A.W. and Boots, R.H.: Effect of Adrenocorticotrophic hormone (ACTH) on Rheumatoid Arthritis. Am. J. Med. 7: 741, 1949.
- Creditor, M.C., Bevans, M., Mundy,
   W.L. and Ragan, C.: Effect of ACTH on Wound Healing in Humans. Pedc.
   SOC. Exper. Biol. Med. 74: 245, 1950.
- Ragan, C., Howes, E.L., Plotz, C.M., Meyer, K. and Blunt, J.W.: Effect of

- cortisone on Production Proc. Soc. Exper. Biol. Med. 72: 718, 1949.
- 31. Howes, E.L., Plotz, C.M., Blunt, J.W., and Ragan, C.: Retardtion of Wound Healing by cortisone: Surgery 28: 177, 1950.
- 32. Alrich, E.M., Carter, J.P. and Lehman, E.P.: Effect of ACTH and Cortisone on Wound Healing: Ann. Surg. 133: 783, 1951.
- Chyun, Y.S., Kream B.E. and Raisz L.G.: Cortisol decreases bone formation by inhibiting periosteal cell prolifeation. Endocrinology 114: 477-480, 1984.
- Key, J.A., Odell, R.T. and Taylor, L.W.: Failure of cortisone to delay or to prevent the healing of fractures in Rats. J. Bone & Joint surg. 34: 665, 1952.
- 35. Dietrich, J.W., Canalis, E.M., Maina, D.M. and Raisz, L.G.: Effect of glu-cocorticoids on fetal rat bone collagen synthesis in vitro Endocrinology 104: 715-721, 1979.
- 36. Seiichi Sato, Takashi Kim, Shichiro Maruyama, Masamishi Tajima and Nobuo Utsumi: Comparison between the Effects of Dexamethasone and Indomethacin on Bone Wound Healing. Japan J. Pharmacol. 42: 71 78, 1986.
- 37. Kumegawa, M., Hiramatsu, M.,

- Hatakeyama, K., Yajima, T., Kodama, H., Osaki, T., Kurisu, K.: Effects of epidermal growth factor on osteoblastic cells in vitro, Calcif. Tissue. Int., 35: 542 548, 1983.
- 38. Hurley, M. M., Abreu, C., Harrison, J. R., Lichtler, A. C., Raiaz, L. G., Kream, B. E.: Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3 E1 cells, J. Biol. Chem., 268: 5588 5593, 1993.
- 39. Sudo, H., Kodama, H., Amagai, Y., Yamamoto, S., Kasai, S.: In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria, J. cell Biol., 96: 191 198, 1983.
- Quarles, L. D., Yohay, D. A., Lever, L. W., Caton, R., Wenstrup, R. J.: Distinct proliferative and differentiated stages of murine MC3T3 E1 cells in culture an in vitro model of osteoblast development, J. Bone Min. Res., 7: 683 692, 1992.
- 41. Choe J Y, Lee B H, Song K B, Park R W, Kim J S, Sohn K Y, Jo J S, Ryoo H M: Expression patterns of bone related proteins during osteoblastic differentiation in MC3T3 E1 cells, J. Cell Biochem., 61: 609 618, 1996.
- 42. Chomczynski, P.: A reagent for the single step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples, BioTechniques 15: 532 537, 1993.
- 43. Aronow, M.A., Gerstenfeld, L.C., Owen, T.A., Tassinari, M.S., Stein,, G.S., and Lian, J.B.: Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells, J. Cell Physiol., 143: 213-221, 1990.




Figure 3




Figure 4




Figure 5



Figure 6




Figure 7




Figure 8

- 44. Robinson, R.: XXXIII. The possible significance of hexosephos phoric esters in ossification, Biochem. J., 111: 286 293, 1923.
- 45. Siffert, R. S.: The role of ALPase in osteogenesis, J. Exp. Med., 93: 415 425, 1951.
- 46. Stein, G. S., Lian, J. B. and Owen, T. A.: Relationship of cell growth to the regulation of tissue specific gene expression during osteoblast differen tion, FASEB. J., 4:82-94, 1990.
- 47. , ; Platelet derived growth factor AA, BB7 , , , 24 : 303 320,1994.
- 49. Nojima, N., Kobayachi, M., Shionomo, H., Takanashi, N., Sudo, T. and Hasegawa, K.: Fibroblastic cells derived from boving periodontal ligaments have the phenotypes of osteoblast, J. Periodont. Res., 25: 179-185, 1990.

- Abstract -

Figure 3. Histochemical change of control group at 10 days

Photomicrograph shows no bone nodules ( $\times$  40).

Figure 4. Histochemical change of on Dex group at 10 days

Photomicrograph shows bone nodules ( $\times$  40).

Figure 5. Histochemical change of control group at 20 days

Photomicrograph shows bone nodules ( $\times$  40).

Figure 6. Histochemical change of Dex group at 20 days

Photomicrograph shows bone nodules( $\times$  40).

Figure 7. Histochemical change of control group at 25 days

Photomicrograph shows bone nodules( $\times$  40).

Figure 8. Histochemical change of Dex group at 25 days

Photomicrograph shows very larger bone nodules than control group( x 40).

## The Effects of Dexamethasone on Growth and Differentia tion of Osteoblast - like Cell

Jae - Mok Lee

Department of Periodontology, School of Dentistry, Kyungpook National University

The ultimate aim of periodontal treatment is periodontal regeneration, which necessiates the regeneration of bone tissues. To evaluate the effects of Dex growth and differentiation of MC3T3 - E1 cells, cells were seeded in alpha - modified eagle medium containing 10% fetal bovine serum, 10mM beta - glycerophosphate ,  $50\mu\text{g/ml}$  of ascorbic acid, with or without  $10^{-7}\text{M}$  Dex and examined cell proliferation activities, alkaline phosphatase activities, and bone nodule formation until 25days.

The results were as follows:

- In Dex group, cell proliferation activities were lower until 15 days compared to control group. Bone nodules formation were showed at 10 days.
- 2. In the time response effect, ALP activities were increased until the 10 days in control groups thereafter decreased and ALP activities of Dex group were lower aspect than control group until the 10 days

In this study, bone nodule formation of osteoblast - like cells were accelerated by Dex and cell proliferation activities, ALP activity of Dex group showed lower than control group. Dex was considered that it did suppress initial growth, but accerelate mineralization of osteoblast - like cells.